We present a case of invasive cutaneous mucormycosis in an elderly man with chronic lymphocytic leukemia (CLL), who was receiving a Bruton tyrosine kinase (BTK)-targeted protein degrader trial drug (BGB-16673), obinutuzumab, a newer anti-CD20 monoclonal therapy, and idelalisib, a phosphoinositide 3-kinase inhibitor. Clinical cure was achieved with limb amputation, given the extent of disease. This case underscores the necessity of a low index of suspicion for mucormycosis on presentation, critical appraisal of the patient's risk factors, and a multimodal approach to diagnosis.

1 month ago

Journal

BTK (Bruton Tyrosine Kinase)

Gazyva (obinutuzumab) • Zydelig (idelalisib) • catadegbrutinib (BGB-16673)

2ms

CaDAnCe-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)

P1/2, N=614, Recruiting, BeiGene | Trial completion date: Dec 2028 --> Nov 2029 | Trial primary completion date: Dec 2025 --> Nov 2026

2 months ago

Trial completion date • Trial primary completion date

catadegbrutinib (BGB-16673)

2ms

BGB-16673-304: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)

P3, N=500, Recruiting, BeiGene | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

Jaypirca (pirtobrutinib) • catadegbrutinib (BGB-16673)

5ms

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)

P1, N=27, Recruiting, BeiGene | Not yet recruiting --> Recruiting

5 months ago

Enrollment open

catadegbrutinib (BGB-16673)

5ms

CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)

P3, N=150, Recruiting, BeiGene | Not yet recruiting --> Recruiting

5 months ago

Enrollment open

Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)

6ms

Diagnosis and Management of Waldenstrom's Macroglobulinemia. (PubMed, Hematol Oncol)

The cBTK-i zanubrutinib shows greater response activity and/or improved progression-free survival in WM patients with wild-type MYD88, mutated CXCR4, or altered TP53. New or emerging options for patients progressing on c-BTKi include pirtobrutinib, BGB-16673, venetoclax, and sonrotoclax. Combinations of BTK inhibitors with chemoimmunotherapy and BCL2 antagonists have advanced. Algorithms for patients with treatment-naïve and previously treated WM based on genomics, disease characteristics, and co-morbidities are discussed.

6 months ago

Review • Journal • IO biomarker

TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)

TP53 mutation

Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib) • sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)

6ms

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)

P1, N=27, Not yet recruiting, BeiGene

6 months ago

New P1 trial

catadegbrutinib (BGB-16673)

7ms

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)

P3, N=500, Not yet recruiting, BeiGene

7 months ago